Medanta Pharmacovigilance Analyst Interview: Rounds, Questions and Preparation

What the job involves

A Pharmacovigilance Analyst monitors, assesses, and reports adverse events and side effects of drugs after they reach the market. Day to day, they review case reports, enter data into safety databases, code events using MedDRA, assess causality and seriousness, and prepare submissions to regulatory authorities like CDSCO or FDA. They also support signal detection and risk management activities to ensure patient safety.

Role and Technical Knowledge

1. 1

   What is pharmacovigilance and why is it important in the healthcare and pharma sector?

   Define pharmacovigilance as the science of detecting, assessing, understanding, and preventing adverse effects. Mention its role in post-marketing surveillance, patient safety, and regulatory compliance.

2. 2

   What are the key steps in processing an adverse event case from receipt to submission?

   Cover triage, data entry, coding with MedDRA, causality and seriousness assessment, quality review, and submission to regulatory authorities within timelines. Highlight accuracy and completeness.

3. 3

   Explain the difference between a serious and a non-serious adverse event. Give examples.

   List seriousness criteria: death, life-threatening, hospitalization, disability, congenital anomaly, or medically important event. Provide examples like anaphylaxis (serious) vs. mild rash (non-serious).

4. 4

   What is MedDRA and how is it used in pharmacovigilance?

   Describe MedDRA as a standardized medical dictionary for regulatory activities. Explain its hierarchy (LLT, PT, HLT, HLGT, SOC) and its role in coding adverse events for consistent analysis.

Practical Scenarios and Case Handling

1. 5

   You receive a report of a patient experiencing severe nausea after taking a new antibiotic. How would you handle it?

   Walk through the case intake process: collect patient details, drug information, event description, and reporter details. Assess seriousness, code the event, and determine if it is expected. If serious and unexpected, report to regulatory authorities within 15 days.

2. 6

   How would you assess causality between a drug and an adverse event?

   Mention causality assessment scales like WHO-UMC or Naranjo. Explain factors: temporal relationship, dechallenge/rechallenge, alternative causes, and biological plausibility. Give a conclusion like 'possible' or 'probable'.

3. 7

   What would you do if you find a discrepancy in a case report during quality check?

   Describe steps: identify the discrepancy, verify with the source document, correct the database, and document the change. Emphasize following SOPs and maintaining data integrity.

4. 8

   How do you handle a case where the reporter is anonymous and information is incomplete?

   Explain that you still process the case, attempt to follow up if possible, and document the missing information. Assess if it meets minimum criteria for a valid case. If not, it may be invalid but still recorded.

Regulatory and Compliance Questions

1. 9

   What are the reporting timelines for adverse events to CDSCO and other regulators?

   For serious unexpected adverse events, 15 calendar days for initial report and 15 days for follow-up. For non-serious, periodic reporting. Mention CDSCO's Pharmacovigilance Programme of India (PvPI) and timelines for SUSARs.

2. 10

   What is ICH-GCP and how does it relate to pharmacovigilance?

   ICH-GCP is a set of guidelines for good clinical practice. In pharmacovigilance, it ensures ethical conduct, data integrity, and safety reporting in clinical trials and post-marketing. Highlight informed consent and safety monitoring.

3. 11

   What is a signal in pharmacovigilance and how is it detected?

   A signal is new information suggesting a causal association between a drug and an event. Detection methods include spontaneous reporting, data mining (e.g., disproportionality analysis), and literature review. Mention signal validation and prioritization.

4. 12

   What is the role of a Periodic Safety Update Report (PSUR)?

   PSUR provides an evaluation of the risk-benefit balance of a drug at defined intervals. It includes cumulative safety data, signal evaluation, and risk minimization measures. Submitted to regulators as per schedule.

Behavioural and HR Questions

1. 13

   Why do you want to work in pharmacovigilance, especially in a hospital or pharma company like Medanta?

   Show passion for patient safety and interest in drug safety monitoring. Mention the opportunity to contribute to public health and work with a reputed healthcare organization. Avoid saying it is just a job.

2. 14

   Describe a time you had to pay close attention to detail to avoid an error.

   Use the STAR method: Situation, Task, Action, Result. Highlight how your vigilance prevented a mistake. Relate it to data accuracy or documentation.

3. 15

   How do you handle working under pressure with strict deadlines?

   Emphasize prioritization, time management, and staying calm. Give an example of meeting a deadline without compromising quality. Mention using checklists or tools.

4. 16

   Where do you see yourself in five years in pharmacovigilance?

   Show ambition to grow into senior analyst, team lead, or specialized areas like signal detection or risk management. Express commitment to continuous learning and certifications.